Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Dual specificity mitogen-activated protein kinase kinase 1

2

Dual specificity mitogen-activated protein kinase kinase 2

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase III

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2020

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Non-small cell lung cancer

2

Thyroid cancer

2

Uveal melanoma

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Array BioPharma

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

ChEMBL

2

DRUG BANK

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SELUMETINIB

6UH91I579U

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2020

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Dual specificity mitogen-activated protein kinase kinase 2

Dual specificity mitogen-activated protein kinase kinase 1

Conditions:

Non-small cell lung cancer

Selumetinib (AZD6244 or ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of Ras-Raf-mitogen-activated protein kinase kinase (MEK1/2). This inhibition can prevent ERK activation, disrupt downstream signal transduction, and inhibit ...

cancer cell proliferation and survival. Selumetinib has shown tumour suppressive activity in multiple rodent models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers. AstraZeneca is responsible for development and commercialization of selumetinib.

PD-254552

6M3XX27BJS

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

SELUMETINIB SULFATE

807ME4B7IJ

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2020

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Dual specificity mitogen-activated protein kinase kinase 2

Dual specificity mitogen-activated protein kinase kinase 1

Conditions:

Non-small cell lung cancer

Selumetinib (AZD6244 or ARRY-142886) is a potent, selective, and ATP-uncompetitive inhibitor of Ras-Raf-mitogen-activated protein kinase kinase (MEK1/2). This inhibition can prevent ERK activation, disrupt downstream signal transduction, and inhibit ...

cancer cell proliferation and survival. Selumetinib has shown tumour suppressive activity in multiple rodent models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers. AstraZeneca is responsible for development and commercialization of selumetinib.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1